Thera-SAbDab

CETUXIMAB

>   Structural Summary
TherapeuticCetuximab
TargetEGFR
Heavy ChainQVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSA
Light ChainDILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELK
100% seqID Fv Structure1yy8 [Fvs: BA, DC], 1yy9 [Fvs: DC], 4gw1 [Fvs: BA, DC], 4gw5 [Fvs: BA, DC], 4kro [Fvs: DC], 4krp [Fvs: DC], 5esq [Fvs: BA, DC], 5etu [Fvs: BA, DC], 5euk [Fvs: BA, DC], 5f88 [Fvs: BA, DC], 5ff6 [Fvs: BA, DC], 5hpm [Fvs: BA, DC], 5hyq [Fvs: BA, DC], 5i2i [Fvs: BA, DC], 5i76 [Fvs: BA, DC], 5icx [Fvs: BA, DC], 5icz [Fvs: BA, DC], 5id1 [Fvs: BA, DC], 5iop [Fvs: BA, DC], 5ir1 [Fvs: BA, DC], 5itf [Fvs: BA, DC], 5iv2 [Fvs: BA, DC], 5ivz [Fvs: BA, DC], 5th2 [Fvs: BA, DC], 6au5 [Fvs: BA, DC], 6axp [Fvs: BA, DC], 6ayn [Fvs: BA, DC], 6azk [Fvs: BA, DC], 6azl [Fvs: BA, DC]
99% seqID Fv Structure5icy [Fvs: BA, DC], 5id0 [Fvs: BA, DC], 5t1k [Fvs: BA, DC], 5t1l [Fvs: BA, DC], 5t1m [Fvs: BA, DC]
95-98% seqID Fv Structure5gz0 [Fvs: BA, DC], 6arp [Fvs: BA, DC], 6aru [Fvs: CB]
>   Alignments

Non-identical sequences have been numbered using the Chothia scheme and aligned to Cetuximab.
CDR positions are indicated in blue. Mismatching positions are highlighted in orange.

Sequence identity: 99.11%

Heavy chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 82A 82B 82C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 100A 100B 100C 101 102 103 104 105 106 107 108 109 110 111 112 113
cetuximab Q V Q L K Q S G P G L V Q P S Q S L S I T C T V S G F S L T N Y G V H W V R Q S P G K G L E W L G V I W S G G N T D Y N T P F T S R L S I N K D N S K S Q V F F K M N S L Q S N D T A I Y Y C A R A L T Y Y D Y E F A Y W G Q G T L V T V S A
5t1k E V Q L K Q S G P G L V Q P S Q S L S I T C T V S G F S L T N Y G V H W V R Q S P G K G L E W L G V I W S G G N T D Y N T P F T S R L S I N K D N S K S Q V F F K M N S L Q S N D T A I Y Y C A R A L T Y Y D Y E F A Y W G Q G T L V T V S -

Light chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107
cetuximab D I L L T Q S P V I L S V S P G E R V S F S C R A S Q S I G T N I H W Y Q Q R T N G S P R L L I K Y A S E S I S G I P S R F S G S G S G T D F T L S I N S V E S E D I A D Y Y C Q Q N N N W P T T F G A G T K L E L K
5t1k D I L L T Q S P V I L S V S P G E R V S F S C R A S Q S I G T N I H W Y Q Q R T N G S P R L L I K Y A S E S I S G I P S R F S G S G S G T D F T L S I N S V E S E D I A D Y Y C Q Q N N N W P T T F G A G T K L E L K
Sequence identity: 99.11%

Heavy chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 82A 82B 82C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 100A 100B 100C 101 102 103 104 105 106 107 108 109 110 111 112 113
cetuximab Q V Q L K Q S G P G L V Q P S Q S L S I T C T V S G F S L T N Y G V H W V R Q S P G K G L E W L G V I W S G G N T D Y N T P F T S R L S I N K D N S K S Q V F F K M N S L Q S N D T A I Y Y C A R A L T Y Y D Y E F A Y W G Q G T L V T V S A
5t1l E V Q L K Q S G P G L V Q P S Q S L S I T C T V S G F S L T N Y G V H W V R Q S P G K G L E W L G V I W S G G N T D Y N T P F T S R L S I N K D N S K S Q V F F K M N S L Q S N D T A I Y Y C A R A L T Y Y D Y E F A Y W G Q G T L V T V S -

Light chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107
cetuximab D I L L T Q S P V I L S V S P G E R V S F S C R A S Q S I G T N I H W Y Q Q R T N G S P R L L I K Y A S E S I S G I P S R F S G S G S G T D F T L S I N S V E S E D I A D Y Y C Q Q N N N W P T T F G A G T K L E L K
5t1l D I L L T Q S P V I L S V S P G E R V S F S C R A S Q S I G T N I H W Y Q Q R T N G S P R L L I K Y A S E S I S G I P S R F S G S G S G T D F T L S I N S V E S E D I A D Y Y C Q Q N N N W P T T F G A G T K L E L K
Sequence identity: 99.11%

Heavy chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 82A 82B 82C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 100A 100B 100C 101 102 103 104 105 106 107 108 109 110 111 112 113
cetuximab Q V Q L K Q S G P G L V Q P S Q S L S I T C T V S G F S L T N Y G V H W V R Q S P G K G L E W L G V I W S G G N T D Y N T P F T S R L S I N K D N S K S Q V F F K M N S L Q S N D T A I Y Y C A R A L T Y Y D Y E F A Y W G Q G T L V T V S A
5id0 E V Q L K Q S G P G L V Q P S Q S L S I T C T V S G F S L T N Y G V H W V R Q S P G K G L E W L G V I W S G G N T D Y N T P F T S R L S I N K D N S K S Q V F F K M N S L Q S N D T A I Y Y C A R A L T Y Y D Y E F A Y W G Q G T L V T V S -

Light chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107
cetuximab D I L L T Q S P V I L S V S P G E R V S F S C R A S Q S I G T N I H W Y Q Q R T N G S P R L L I K Y A S E S I S G I P S R F S G S G S G T D F T L S I N S V E S E D I A D Y Y C Q Q N N N W P T T F G A G T K L E L K
5id0 D I L L T Q S P V I L S V S P G E R V S F S C R A S Q S I G T N I H W Y Q Q R T N G S P R L L I K Y A S E S I S G I P S R F S G S G S G T D F T L S I N S V E S E D I A D Y Y C Q Q N N N W P T T F G A G T K L E L K
Sequence identity: 99.11%

Heavy chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 82A 82B 82C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 100A 100B 100C 101 102 103 104 105 106 107 108 109 110 111 112 113
cetuximab Q V Q L K Q S G P G L V Q P S Q S L S I T C T V S G F S L T N Y G V H W V R Q S P G K G L E W L G V I W S G G N T D Y N T P F T S R L S I N K D N S K S Q V F F K M N S L Q S N D T A I Y Y C A R A L T Y Y D Y E F A Y W G Q G T L V T V S A
5icy E V Q L K Q S G P G L V Q P S Q S L S I T C T V S G F S L T N Y G V H W V R Q S P G K G L E W L G V I W S G G N T D Y N T P F T S R L S I N K D N S K S Q V F F K M N S L Q S N D T A I Y Y C A R A L T Y Y D Y E F A Y W G Q G T L V T V S -

Light chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107
cetuximab D I L L T Q S P V I L S V S P G E R V S F S C R A S Q S I G T N I H W Y Q Q R T N G S P R L L I K Y A S E S I S G I P S R F S G S G S G T D F T L S I N S V E S E D I A D Y Y C Q Q N N N W P T T F G A G T K L E L K
5icy D I L L T Q S P V I L S V S P G E R V S F S C R A S Q S I G T N I H W Y Q Q R T N G S P R L L I K Y A S E S I S G I P S R F S G S G S G T D F T L S I N S V E S E D I A D Y Y C Q Q N N N W P T T F G A G T K L E L K
Sequence identity: 99.11%

Heavy chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 82A 82B 82C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 100A 100B 100C 101 102 103 104 105 106 107 108 109 110 111 112 113
cetuximab Q V Q L K Q S G P G L V Q P S Q S L S I T C T V S G F S L T N Y G V H W V R Q S P G K G L E W L G V I W S G G N T D Y N T P F T S R L S I N K D N S K S Q V F F K M N S L Q S N D T A I Y Y C A R A L T Y Y D Y E F A Y W G Q G T L V T V S A
5t1m E V Q L K Q S G P G L V Q P S Q S L S I T C T V S G F S L T N Y G V H W V R Q S P G K G L E W L G V I W S G G N T D Y N T P F T S R L S I N K D N S K S Q V F F K M N S L Q S N D T A I Y Y C A R A L T Y Y D Y E F A Y W G Q G T L V T V S -

Light chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107
cetuximab D I L L T Q S P V I L S V S P G E R V S F S C R A S Q S I G T N I H W Y Q Q R T N G S P R L L I K Y A S E S I S G I P S R F S G S G S G T D F T L S I N S V E S E D I A D Y Y C Q Q N N N W P T T F G A G T K L E L K
5t1m D I L L T Q S P V I L S V S P G E R V S F S C R A S Q S I G T N I H W Y Q Q R T N G S P R L L I K Y A S E S I S G I P S R F S G S G S G T D F T L S I N S V E S E D I A D Y Y C Q Q N N N W P T T F G A G T K L E L K
Sequence identity: 98.23%

Heavy chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 82A 82B 82C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 100A 100B 100C 101 102 103 104 105 106 107 108 109 110 111 112 113
cetuximab Q V Q L K Q S G P G L V Q P S Q S L S I T C T V S G F S L T N Y G V H W V R Q S P G K G L E W L G V I W S G G N T D Y N T P F T S R L S I N K D N S K S Q V F F K M N S L Q S N D T A I Y Y C A R A L T Y Y D Y E F A Y W G Q G T L V T V S A
6arp Q V Q L K Q S G P G L V Q P S Q S L S I T C T V S G F D L T D Y G V H W V R Q S P G K G L E W L G V I W S G G N T D Y N T P F T S R L S I N K D N S K S Q V F F K M N S L Q S N D T A I Y Y C A R A L T Y Y D Y E F A Y W G Q G T L V T V S A

Light chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107
cetuximab D I L L T Q S P V I L S V S P G E R V S F S C R A S Q S I G T N I H W Y Q Q R T N G S P R L L I K Y A S E S I S G I P S R F S G S G S G T D F T L S I N S V E S E D I A D Y Y C Q Q N N N W P T T F G A G T K L E L K
6arp D I L L T Q S P V I L S V S P G E R V S F S C R A S Q S I G T N I H W Y Q Q R T N G S P R L L I K Y A D E S I D G I P S R F S G S G S G T D F T L S I N S V E S E D I A D Y Y C Q Q N N N W P T T F G A G T K L E L K
Sequence identity: 98.23%

Heavy chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 82A 82B 82C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 100A 100B 100C 101 102 103 104 105 106 107 108 109 110 111 112 113
cetuximab Q V Q L K Q S G P G L V Q P S Q S L S I T C T V S G F S L T N Y G V H W V R Q S P G K G L E W L G V I W S G G N T D Y N T P F T S R L S I N K D N S K S Q V F F K M N S L Q S N D T A I Y Y C A R A L T Y Y D Y E F A Y W G Q G T L V T V S A
6aru Q V Q L K Q S G P G L V Q P S Q S L S I T C T V S G F D L T D Y G V H W V R Q S P G K G L E W L G V I W S G G N T D Y N T P F T S R L S I N K D N S K S Q V F F K M N S L Q S N D T A I Y Y C A R A L T Y Y D Y E F A Y W G Q G T L V T V S A

Light chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107
cetuximab D I L L T Q S P V I L S V S P G E R V S F S C R A S Q S I G T N I H W Y Q Q R T N G S P R L L I K Y A S E S I S G I P S R F S G S G S G T D F T L S I N S V E S E D I A D Y Y C Q Q N N N W P T T F G A G T K L E L K
6aru D I L L T Q S P V I L S V S P G E R V S F S C R A S Q S I G T N I H W Y Q Q R T N G S P R L L I K Y A D E S I D G I P S R F S G S G S G T D F T L S I N S V E S E D I A D Y Y C Q Q N N N W P T T F G A G T K L E L K
Sequence identity: 97.78%

Heavy chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 82A 82B 82C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 100A 100B 100C 101 102 103 104 105 106 107 108 109 110 111 112 113
cetuximab Q V Q L K Q S G P G L V Q P S Q S L S I T C T V S G F S L T N Y G V H W V R Q S P G K G L E W L G V I W S G G N T D Y N T P F T S R L S I N K D N S K S Q V F F K M N S L Q S N D T A I Y Y C A R A L T Y Y D Y E F A Y W G Q G T L V T V S A
5gz0 Q V Q L K Q S G P G L V Q P G G S L S I T C T V S G F S L T N Y G V H W V R Q S P G K G L E W L G V I W S G G N T D Y N T P F T S R L S I N K D N S K S Q V F F K M N S L Q S N D T A I Y Y C A R A L T Y Y D Y E F A Y W G Q G T L V T V S -

Light chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107
cetuximab D I L L T Q S P V I L S V S P G E R V S F S C R A S Q S I G T N I H W Y Q Q R T N G S P R L L I K Y A S E S I S G I P S R F S G S G S G T D F T L S I N S V E S E D I A D Y Y C Q Q N N N W P T T F G A G T K L E L K
5gz0 D I Q M T Q S P V I L S V S P G E R V S F S C R A S Q S I G T N I H W Y Q Q R T N G S P R L L I K Y A S E S I S G I P S R F S G S G S G T D F T L S I N S V E S E D I A D Y Y C Q Q N N N W P T T F G A G T K L E L K
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (August '23)Approved
Estimated Status (August '23)Active
Recorded Developmental Technologyna
INN Year Proposed1999
INN Year Recommended2000
Companies InvolvedArray BioPharma, Bristol-Myers Squibb, Celldex Therapeutics Inc, Centre Jean Perrin, Eli Lilly, Merck KGaA, New York University School of Medicine, Novartis, Pierre Fabre, Roche, University Hospital Ghent, University of California, University of Heidelberg, University of Michigan Comprehensive Cancer Center
Conditions ApprovedColorectal cancer, Head and neck cancer
Conditions ActiveNon-small cell lung cancer, Bladder cancer, Breast cancer, Gastric cancer, Mesothelioma, Rectal cancer, Squamous cell cancer, Adenoid cystic carcinoma, Oesophageal cancer
Conditions DiscontinuedPancreatic cancer, Prostate cancer
Notesna

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]

Our privacy policy